Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia--precursor of endometrial cancer (Q44315208)

1 December 2017

Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia--precursor of endometrial cancer (English)

1 reference

1 December 2017

Sa Wang

1

1 reference

1 December 2017

Jeffery Pudney

2

1 reference

1 December 2017

Joon Song

3

1 reference

1 December 2017

Gil Mor

4

1 reference

1 December 2017

Peter E Schwartz

5

1 reference

1 December 2017

Wenxin Zheng

6

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

1 December 2017

1 reference

1 December 2017

88

1 reference

1 December 2017

2

1 reference

1 December 2017

108-117

1 reference

The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Progestin therapy in endometrial hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high- and low-dose estrogen-progestin regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Hormonal pathology of the endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Do estrogen and progesterone receptors (E2R and PR) in metastasizing endometrial cancers predict the response to gestagen therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Estradiol and progesterone receptors in normal and neoplastic endometrium: Correlations between receptors, histopathological examinations and clinical responses under progestin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following downregulation of tumor progesterone receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

TNFalpha expression in hyperplastic endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Down-regulation of bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Apoptosis may be an early event of progestin therapy for endometrial hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Serum deprivation-induced apoptosis in cultured porcine granulosa cells is characterized by increased expression of p53 protein, Fas antigen and Fas ligand and by decreased expression of PCNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Fas ligand, Fas antigen and Bcl-2 expression in human endometrium during the menstrual cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Bcl-2 and Fas expression in eutopic and ectopic human endometrium during the menstrual cycle in relation to endometrial cell apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Roles of Fas and Fas ligand during mammary gland remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Fas-induced apoptosis, and diseases caused by its abnormality

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Apoptosis induction by caspase-8 is amplified through the mitochondrial release of cytochrome c.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Matrix metalloproteinase expression in Macaca mulatta endometrium: evidence for zone-specific regulatory tissue gradients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Regulation of fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Pleiotypic actions of the seminiferous growth factor on two testicular cell lines: comparisons with acidic and basic fibroblast growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Apoptosis in the human uterine endometrium during the menstrual cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Bcl-2, Fas and caspase 3 expression in endometrium from levonorgestrel implant users with and without breakthrough bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Site and menstrual cycle-dependent expression of proteins of the tumour necrosis factor (TNF) receptor family, and BCL-2 oncoprotein and phase-specific production of TNF alpha in human endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Bcl-x(L) can inhibit apoptosis in cells that have undergone Fas-induced protease activation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Metalloproteinase-mediated release of human Fas ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

Regulation of Fas ligand expression by estradiol and progesterone in human endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900008-2

7 January 2021

10.1016/S0090-8258(02)00008-2

Identifiers

DOI

1 reference

1 December 2017

1 reference